Boehringer Ingelheim receives FDA approval for NexGard Plus
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
Moist wound dressing for chronic wound treatment now available in Germany
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
Subscribe To Our Newsletter & Stay Updated